Amgen Inc. AMGN.TO
AMGN.TO Rating
AMGN.TO Rating Factors
AMGN.TO Company Overview
Amgen Inc. is a U.S.-based biotechnology company focused on the discovery, development, manufacturing, and commercialization of human therapeutics. The company operates primarily within the biotechnology and biopharmaceutical industries, with products spanning oncology, inflammation, bone health, cardiovascular disease, nephrology, and rare diseases. Amgen’s revenue is driven largely by biologic medicines, biosimilars, and specialty therapeutics marketed to hospitals, specialty pharmacies, healthcare providers, and government health systems. Major commercial products include therapies such as Enbrel, Prolia, XGEVA, Otezla, Repatha, and TEPEZZA, along with a growing biosimilars portfolio.
Founded in 1980 as Applied Molecular Genetics, Amgen was among the earliest biotechnology firms to successfully commercialize recombinant DNA-based medicines. The company expanded significantly through internal research and strategic acquisitions, evolving from an early biotechnology pioneer into one of the world’s largest independent biopharmaceutical companies. Amgen’s strategic positioning has historically centered on biologics manufacturing expertise, strong intellectual property capabilities, large-scale commercial infrastructure, and long product life cycles supported by advanced biologic development platforms.
AMGN.TO Income Statement
AMGN.TO Balance Sheet
AMGN.TO Price History
AMGN.TO Valuation
AMGN.TO Dividends and Shares
AMGN.TO Corporate Info
Thousand Oaks, CA 91320-1799